<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02125604</url>
  </required_header>
  <id_info>
    <org_study_id>109MS407</org_study_id>
    <secondary_id>2013-001486-17</secondary_id>
    <nct_id>NCT02125604</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany</brief_title>
  <acronym>TOLERATE</acronym>
  <official_title>A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of symptomatic therapies on
      gastrointestinal-related events reported by participants with relapsing-remitting multiple
      sclerosis initiating therapy with BG00012 (dimethyl fumarate, DMF) in the clinical practice
      setting.

      The secondary objectives of this study in this study population are as follows: to evaluate
      gastrointestinal-related events requiring symptomatic therapy and the role of those therapies
      over time; to evaluate gastrointestinal-related events that lead to a physician's decision to
      manage the events with BG00012 dose modification; and to evaluate gastrointestinal-related
      events that lead to BG00012 discontinuation after the use of symptomatic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The MOGISS is a questionnaire about the severity of overall gastrointestinal-related events, including specifically symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence for 24 hours before the AM dose. Participants who rated the intensity of symptoms reported on the MOGISS and included each symptomatic therapy used in the eDiary are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The MAGISS is a questionnaire in which participants reported overall acute gastrointestinal-related events, (especially symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) for each 10 hours after the AM and PM doses of study drug. Participants who rated the intensity of gastrointestinal-related events reported on MAGISS, included the duration of the gastrointestinal-related events and each symptomatic therapy used in the eDiary are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The MOGISS is a questionnaire about overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. MOGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The MAGISS is a questionnaire about the overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) following drug administration (acute symptoms). MAGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The percentage of days with GI events as reported on MOGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with [GI] events / # of days tolerability scale completed). The symptomatic therapy (ST) categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of days with GI events as reported on MAGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with [GI] events / # of days tolerability scale completed). The ST categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
    <description>The cumulative percentage of dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis who required symptomatic therapy up to Week 4, Week 8, and Week 12 were estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Symptomatic therapies were classified into 10 main categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (includes Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon &amp; Iberogast, Iberogast &amp; Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (non-steroidal anti-inflammatory drug [NSAID]; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). Participants may have taken &gt; 1 symptomatic therapy but were counted only once for the 'All therapies' summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Symptomatic therapies were classified into 10 categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (eg, Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon &amp; Iberogast, Iberogast &amp; Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (NSAID; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in 'All therapies'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Dose reductions are defined as participants who take any dimethyl fumarate 120 mg or 0 mg since initiation of dimethyl fumarate 240 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dimethyl Fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimethyl fumarate</intervention_name>
    <description>capsules administered according to the prevailing product label</description>
    <arm_group_label>Dimethyl Fumarate</arm_group_label>
    <other_name>BG00012</other_name>
    <other_name>Tecfidera</other_name>
    <other_name>DMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Have a confirmed diagnosis of relapsing-remitting multiple sclerosis according to the
             current McDonald Criteria and satisfy the therapeutic indication as described in the
             official local registration for Tecfidera (dimethyl fumarate)

          -  Naïve to dimethyl fumarate and fumaric acid esters

        Key Exclusion Criteria:

          -  Female subjects who are currently pregnant or breastfeeding or who are considering
             becoming pregnant while in the study

          -  History of significant gastrointestinal disease (e.g., irritable bowel disease, peptic
             ulcer disease, history of major gastrointestinal surgeries), or chronic use of
             gastrointestinal-related symptomatic therapy as determined by the Investigator (or ≥ 7
             consecutive days of gastrointestinal-related symptomatic therapy

          -  Known active malignancies

          -  History of anaphylaxis or severe allergic reactions or known drug hypersensitivity

          -  Current use of B vitamin supplements

          -  In the opinion of the Investigator, blood test values suggestive of a low lymphocyte
             count or renal or hepatic impairment, as described in the product label precautions
             for use

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mittweida</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osnabruck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siegen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <results_first_submitted>March 7, 2017</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2017</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 214 participants were screened and enrolled; 3 participants did not receive study drug (1 withdrew consent and 2 did not meet all inclusion/exclusion criteria). A total of 211 participants were included in the safety population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dimethyl Fumarate</title>
          <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="211">enrolled and received at least 1 dose of study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dimethyl Fumarate</title>
          <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.09" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)</title>
        <description>The MOGISS is a questionnaire about the severity of overall gastrointestinal-related events, including specifically symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence for 24 hours before the AM dose. Participants who rated the intensity of symptoms reported on the MOGISS and included each symptomatic therapy used in the eDiary are presented.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate; n=participants with an assessment during given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)</title>
          <description>The MOGISS is a questionnaire about the severity of overall gastrointestinal-related events, including specifically symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence for 24 hours before the AM dose. Participants who rated the intensity of symptoms reported on the MOGISS and included each symptomatic therapy used in the eDiary are presented.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate; n=participants with an assessment during given time period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Treatment Period; n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1-4; n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 5-8; n=186</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 9-12; n=178</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)</title>
        <description>The MAGISS is a questionnaire in which participants reported overall acute gastrointestinal-related events, (especially symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) for each 10 hours after the AM and PM doses of study drug. Participants who rated the intensity of gastrointestinal-related events reported on MAGISS, included the duration of the gastrointestinal-related events and each symptomatic therapy used in the eDiary are presented.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate; n=participants with an assessment during given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)</title>
          <description>The MAGISS is a questionnaire in which participants reported overall acute gastrointestinal-related events, (especially symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) for each 10 hours after the AM and PM doses of study drug. Participants who rated the intensity of gastrointestinal-related events reported on MAGISS, included the duration of the gastrointestinal-related events and each symptomatic therapy used in the eDiary are presented.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate; n=participants with an assessment during given time period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Treatment Period; n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1-4; n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 5-8; n=189</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 9-12; n=180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS</title>
        <description>The MOGISS is a questionnaire about overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. MOGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS</title>
          <description>The MOGISS is a questionnaire about overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. MOGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall treatment period; n=84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" spread="2.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; n=73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="2.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; n=38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="2.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; n=29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS</title>
        <description>The MAGISS is a questionnaire about the overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) following drug administration (acute symptoms). MAGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS</title>
          <description>The MAGISS is a questionnaire about the overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) following drug administration (acute symptoms). MAGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall treatment period; n=84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="2.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; n=73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" spread="2.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; n=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="2.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; n=29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="2.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS</title>
        <description>The percentage of days with GI events as reported on MOGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with [GI] events / # of days tolerability scale completed). The symptomatic therapy (ST) categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS</title>
          <description>The percentage of days with GI events as reported on MOGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with [GI] events / # of days tolerability scale completed). The symptomatic therapy (ST) categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall treatment period; Any ST (n=84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.13" spread="29.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST1 (n=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.08" spread="27.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST2 (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.98" spread="29.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST3 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.61" spread="29.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST4 (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.15" spread="30.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST5 (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.94" spread="27.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST6 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.33" spread="29.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST7 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.52" spread="21.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST8 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.71" spread="31.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST9 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.78" spread="26.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST10 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.20" spread="2.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; Any ST (n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.58" spread="29.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST1 (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.92" spread="27.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST2 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.53" spread="32.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST3 (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.31" spread="29.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST4 (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.63" spread="25.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST5 (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.42" spread="32.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST6 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.48" spread="35.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST7 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.78" spread="24.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST8 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.43" spread="31.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST9 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.41" spread="34.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST10 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; Any ST (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.55" spread="38.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST1 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.04" spread="41.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.67" spread="52.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST3 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.45" spread="37.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST4 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.14" spread="44.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST5 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.75" spread="31.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST6 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.42" spread="25.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST7 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71">1 participant used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST8 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.88" spread="40.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST9 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST10 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="2.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; Any ST (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.27" spread="42.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST1 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.66" spread="43.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.72" spread="29.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST3 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.85" spread="50.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST4 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.12" spread="20.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST5 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.50" spread="53.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST6 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST7 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST8 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="13.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST9 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST10 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12</title>
        <description>The cumulative percentage of dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis who required symptomatic therapy up to Week 4, Week 8, and Week 12 were estimated using the Kaplan-Meier method.</description>
        <time_frame>Week 4, Week 8, Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12</title>
          <description>The cumulative percentage of dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis who required symptomatic therapy up to Week 4, Week 8, and Week 12 were estimated using the Kaplan-Meier method.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category</title>
        <description>Symptomatic therapies were classified into 10 main categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (includes Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon &amp; Iberogast, Iberogast &amp; Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (non-steroidal anti-inflammatory drug [NSAID]; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). Participants may have taken &gt; 1 symptomatic therapy but were counted only once for the 'All therapies' summary.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category</title>
          <description>Symptomatic therapies were classified into 10 main categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (includes Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon &amp; Iberogast, Iberogast &amp; Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (non-steroidal anti-inflammatory drug [NSAID]; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). Participants may have taken &gt; 1 symptomatic therapy but were counted only once for the 'All therapies' summary.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall treatment period (OTP): All therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-acid production</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-bloating/anti-constipation agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Multi-target/herbal agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-diarrheal (anti-peristaltic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Analgesic (NSAID)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-emetic (central)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-emetic (pro-kinetic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Antacid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Laxative (pro-kinetic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: All therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-acid production</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-bloating/anti-constipation agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Multi-target/herbal agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-diarrheal (anti-peristaltic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Analgesic (NSAID)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-emetic (central)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-emetic (pro-kinetic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Antacid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: All therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-acid production</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Multi-target/herbal agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Analgesic (NSAID)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-bloating/anti-constipation agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-diarrheal (anti-peristaltic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-emetic (central)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Antacid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Laxative (pro-kinetic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-emetic (pro-kinetic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: All therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Anti-acid production</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Multi-target/herbal agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Anti-diarrheal (anti-peristaltic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Anti-bloating.anti-constipation agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Analgesic (NSAID)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Antacid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category</title>
        <description>Symptomatic therapies were classified into 10 categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (eg, Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon &amp; Iberogast, Iberogast &amp; Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (NSAID; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in 'All therapies'.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category</title>
          <description>Symptomatic therapies were classified into 10 categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (eg, Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon &amp; Iberogast, Iberogast &amp; Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (NSAID; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in 'All therapies'.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OTP: All therapies; n=84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.15" spread="19.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-acid production; n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.62" spread="22.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-bloating/anti-constipation agent; n=26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Multi-target/herbal agents; n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-diarrheal (anti-peristaltic); n=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Analgesic (NSAID); n=10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-emetic (central); n=8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Anti-emetic (pro-kinetic); n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Antacid; n=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Other; n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTP: Laxative (pro-kinetic); n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: All therapies; n=73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-acid production; n=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-bloating/anti-constipation; n=23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Multi-target/herbal agents; n=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-diarrheal (anti-peristaltic); n=13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Analgesic (NSAID); n=9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-emetic (central); n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Anti-emetic (pro-kinetic); n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Antacid; n=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4: Other; n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: All therapies; n=38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.08" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-acid production; n=23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.00" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Multi-target/herbal agents; n=8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.50" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Analgesic (NSAID); n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-bloating/anti-constipation; n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-diarrheal (anti-peristaltic); n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-emetic (central); n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Antacid; n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Laxative (pro-kinetic); n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8: Anti-emetic (prokinetic); n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">One participant only was included.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: All therapies; n=29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Anti-acid production; n=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.73" spread="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Multi-target/herbal agents; n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Anti-diarrheal (anti-peristaltic); n=4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Anti-bloating/anti-constipation; n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Analgesic (NSAID); n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12: Antacid; n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events</title>
        <description>Dose reductions are defined as participants who take any dimethyl fumarate 120 mg or 0 mg since initiation of dimethyl fumarate 240 mg.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events</title>
          <description>Dose reductions are defined as participants who take any dimethyl fumarate 120 mg or 0 mg since initiation of dimethyl fumarate 240 mg.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events</title>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events</title>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS</title>
        <description>Percentage of days with GI events as reported on MAGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with [GI] events / # of days tolerability scale completed). The ST categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dimethyl Fumarate</title>
            <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS</title>
          <description>Percentage of days with GI events as reported on MAGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with [GI] events / # of days tolerability scale completed). The ST categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.</description>
          <population>Safety Population: all participants who received at least 1 dose of dimethyl fumarate and used symptomatic therapy; n=participants with an evaluable assessment during given time period.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall treatment period; Any ST (n=84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.20" spread="30.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST1 (n=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.29" spread="29.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST2 (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.67" spread="27.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST3 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.28" spread="29.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST4 (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.94" spread="33.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST5 (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.65" spread="27.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST6 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.71" spread="30.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST7 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.32" spread="23.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST8 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.42" spread="31.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST9 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.92" spread="27.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall treatment period; ST10 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.88" spread="1.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; Any ST (n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.03" spread="30.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST1 (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.41" spread="29.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST2 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.84" spread="30.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST3 (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.67" spread="30.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST4 (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.90" spread="27.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST5 (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.74" spread="32.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST6 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.43" spread="33.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST7 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.54" spread="25.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST8 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.86" spread="28.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST9 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.61" spread="47.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-4; ST10 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; Any ST (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.59" spread="37.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST1 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.59" spread="41.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.14" spread="45.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST3 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.50" spread="35.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST4 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.58" spread="45.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST5 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.33" spread="33.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST6 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.61" spread="24.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST7 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71">1 participant used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST8 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.24" spread="32.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST9 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8; ST10 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="14.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; Any ST (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.28" spread="42.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST1 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.24" spread="44.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.19" spread="41.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST3 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.99" spread="50.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST4 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.48" spread="10.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST5 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.16" spread="52.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST6 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST7 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST8 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.11" spread="7.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST9 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12; ST10 (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants used this symptomatic therapy in this time period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events: from signing of informed consent through last dose (up to 12 weeks (±5 days) plus 2 weeks (±5 days) follow up. Adverse events: from time of first dose of dimethyl fumarate through last dose (up to 12 weeks (±5 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dimethyl Fumarate</title>
          <description>Dimethyl fumarate administered orally at 120 mg BID for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increrased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Study Medical Director</name_or_title>
      <organization>Biogen</organization>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

